In this study, we utilized a stepwise approach to modifying CAR components (Table 1) and observed that NK-tailored CAR, particularly NK-CAR12 incorporating the signaling domains of DAP10, 2B4, and CD3ζ coupled to CD8α H and CD28 TM, outperforms the conventional T-CAR currently used to treat hematological malignancies. Here, CD28 is linked to hematologic disorder.